Revisiting the Incidence of Tardive Dyskinesia With Oral Metoclopramide Use: A Real‐World Epidemiology Study (2011–2020)

Key Points

Uncommon incidence of tardive dyskinesia is observed with metoclopramide use, indicating it may be a safer option.
Evidence shows TD incidence is lower than previously estimated in instances of gastroparesis treatment.
Analysis using real-world data from 2011 to 2020 provides a contemporary perspective on TD risk with metoclopramide.
Highlights the need to reassess the risk-benefit profile of metoclopramide in managing gastroparesis patients.

Abstract

TD incidence is uncommon with metoclopramide use and lower than previously estimated in gastroparesis patients. These findings suggest metoclopramide may be a viable treatment option and warrant a reassessment of its risk-benefit profile in gastroparesis management.

Revisiting the Incidence of Tardive Dyskinesia With Oral Metoclopramide Use: A Real‐World Epidemiology Study (2011–2020)

Key Points

Abstract

Cite This Study